0000950123-21-011522.txt : 20210816
0000950123-21-011522.hdr.sgml : 20210816
20210816162301
ACCESSION NUMBER: 0000950123-21-011522
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210630
FILED AS OF DATE: 20210816
DATE AS OF CHANGE: 20210816
EFFECTIVENESS DATE: 20210816
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC
CENTRAL INDEX KEY: 0001703031
IRS NUMBER: 813996001
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-18477
FILM NUMBER: 211178644
BUSINESS ADDRESS:
STREET 1: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6175162878
MAIL ADDRESS:
STREET 1: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
13F-HR
1
primary_doc.xml
13F-HR
LIVE
0001703031
XXXXXXXX
06-30-2021
06-30-2021
false
Bain Capital Life Sciences Investors, LLC
200 Clarendon Street
Boston
MA
02116
13F HOLDINGS REPORT
028-18477
Y
Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP and (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general parter of Bain Capital Life Sciences Fund II, L.P.The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on Amendment No. 3 to the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on June 11, 2021 and reflect the conversion of securities convertible into shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such conversion. As of June 30, 2021, such persons held an aggregate of 8,525,000 shares of DVAX common stock. The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on Amendment No. 1 the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on March 17, 2021 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of June 30, 2021, such persons held an aggregate of 6,913,208 shares of SVRA common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS" ) included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 14, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise or conversion. As of June 30, 2021, such persons held an aggregate of 5,504,661 shares of SYRS common stock.
Adam Koppel
Managing Dir. of Bain Capital Life Sciences Investors, LLC
617-516-2000
/s/ Adam Koppel
Boston
MA
08-16-2021
5
30
1526199
false
1
28-18476
Bain Capital Life Sciences Partners, LP
2
28-18478
Bain Capital Life Sciences Fund, L.P.
3
28-20270
BC SW, LP
4
28-20816
Bain Capital Life Sciences Investors II, LLC
5
28-20814
Bain Capital Life Sciences Fund II, L.P.
INFORMATION TABLE
2
5373.xml
INFORMATION TABLE FOR FORM 13F
DICERNA PHARMACEUTICALS INC
COM
253031108
114954
3080237
SH
SOLE
3080237
0
0
MARINUS PHARMACEUTICALS INC
COM
56854Q200
25673
1431058
SH
SOLE
1431058
0
0
SOLID BIOSCIENCES INC
COM
83422E105
29024
7929918
SH
SOLE
7929918
0
0
APTINYX INC
COM
03836N103
25164
8891758
SH
SOLE
8891758
0
0
SPRINGWORKS THERAPEUTICS INC
COM
85205L107
480558
5831307
SH
SOLE
5831307
0
0
DYNAVAX TECHNOLOGIES CORP
COM
268158201
115951
11771708
SH
SOLE
11771708
0
0
X4 PHARMACEUTICALS INC
COM
98420X103
13777
2119540
SH
SOLE
2119540
0
0
SAVARA INC
COM
805111101
19758
11622598
SH
SOLE
11622598
0
0
ARCUTIS BIOTHERAPEUTICS INC.
COM
03969K108
108595
3979292
SH
SOLE
3979292
0
0
MERSANA THERAPEUTICS INC.
COM
59045L106
50187
3695667
SH
SOLE
3695667
0
0
CRINETICS PHARMACEUTICALS
COM
22663K107
31662
1679701
SH
SOLE
1679701
0
0
AEGLEA BIO THERAPEUTICS INC
COM
00773J103
18792
2700000
SH
SOLE
2700000
0
0
ANNEXON INC
COM
03589W102
72969
3241628
SH
SOLE
3241628
0
0
NURIX THERAPEUTICS INC
COM
67080M103
34073
1284314
SH
SOLE
1284314
0
0
KYMERA THERAPEUTICS INC.
COM
501575104
23261
479605
SH
SOLE
479605
0
0
RESEARCH ALLIANCE CORP II
COM CL A
760873109
10140
1000000
SH
SOLE
1000000
0
0
NAUTILUS BIOTECHNOLOGY INC.
COM
63909J108
20200
2000000
SH
SOLE
2000000
0
0
BCTG ACQUISITION CORP
COM
05492W103
10490
921790
SH
SOLE
921790
0
0
SYROS PHARMACEUTICALS INC.
COM
87184Q107
31528
5785036
SH
SOLE
5785036
0
0
ATEA PHARMACEUTICALS, INC.
COM
04683R106
120624
5615659
SH
SOLE
5615659
0
0
C4 THERAPEUTICS, INC.
COM STK
12529R107
62141
1642209
SH
SOLE
1642209
0
0
BCLS ACQUISITION CORP
COM CL A
G0904B105
5133
487500
SH
SOLE
487500
0
0
JIYA ACQUISITION CORP
COM CL A
47760M102
2982
300000
SH
SOLE
300000
0
0
HELIX ACQUISITION CORP
COM CL A
G4444C102
2588
250000
SH
SOLE
250000
0
0
FRAZIER LIFESCIENCES ACQU CO
UNIT 12/09/2025
G3710A121
3015
300000
SH
SOLE
300000
0
0
PHARVARIS N.V.
COM
N69605108
59255
3180601
SH
SOLE
3180601
0
0
ARYA SCIENCES ACQU CORP IV
CL A
G31659108
7504
700000
SH
SOLE
700000
0
0
PANACEA ACQUISITION CORP II
CL A SHS
G6882C106
5010
500000
SH
SOLE
500000
0
0
BLUEBIRD BIO, INC.
COM
09609G100
17211
538179
SH
SOLE
538179
0
0
OMEGA ALPHA SPAC
CL A
G6749V107
3980
400000
SH
SOLE
400000
0
0